Accelerating researchers’ access to next-generation light-sheet microscopy

EMBL spin-off company Luxendo has been acquired by the Bruker Corporation. Based in Heidelberg, Germany, Luxendo develops and commercialises microscopes that use the Single Plane Illumination Microscopy (SPIM) technique developed by EMBL researchers.

“It has been very rewarding to witness the rapid trajectory from pioneering technology developed at EMBL to Luxendo’s well-designed, robust microscopes, and now this acquisition,” said EMBL Director General Iain Mattaj. “We anticipate that Bruker, with its excellent reputation in providing innovative technology, will make SPIM even more widely available. It will be truly exciting to see what the larger biological research community will discover with light-sheet microscopy.”

The SPIM technology enables scientists to watch entire living organisms in exquisite detail, thanks to its ability to rapidly image large 3-dimensional samples while causing them minimal damage. To make this technology available to the scientific community, EMBL and its technology transfer arm, EMBLEM Technology Transfer (EMBLEM), created Luxendo as a spin-off company in 2015, with seed financing from EMBL Ventures and Life Science Partners (LSP). The spin-off’s first two products, MuVi-SPIM and InVi-SPIM were launched in 2016.

“With its strong IP position and unique SPIM technology, Luxendo has quickly established itself in the light-sheet microscopy market, particularly in Europe,” said Dr. Mark R. Munch, President of the Bruker NANO Group. “Similar to our recent acquisition in super-resolution microscopy, the new capabilities provide valuable application synergies to our current suite of instruments, and we feel that we can take the business to the next level in both global market reach and next-generation development, which should greatly benefit our life sciences research customers.”

“The successful partnering of Luxendo with Bruker within 18 months of spin-off creation was only possible due to the excellent collaboration within EMBL’s unique technology transfer and innovation ecosystem: innovative EMBL researchers paired with experienced technology transfer managers at EMBLEM and investment managers at EMBL Ventures,” stated Jürgen Bauer, Deputy Managing Director of EMBLEM, EMBL’s wholly owned technology and knowledge transfer subsidiary.  

______________________________________________________________________________________________________________

About Luxendo

Luxendo develops and internationally markets its Single Plane Illumination Microscopes, which are based on its proprietary Single Plane Illumination Microscopy (SPIM) technology. It was created as a spin-off company by EMBL and EMBL’s technology transfer arm, EMBLEM, in 2015. The company launched the MuVi-SPIM and InVi-SPIM microscopes in 2016. Both microscopes avoid sample phototoxicity by sequentially illuminating a stack of small slices of the organism, allowing scientists to observe living organisms for extended periods of time without photodamage. The MuVi-SPIM microscope allows fast 3D imaging of living objects, such as spheroids and whole specimens without the need of sample rotation. The InVi-SPIM microscope enables fast 3D imaging with extremely gentle sample handling for cell cultures and developing embryonic samples. For more information, please visit Luxendo's website.

Staatz Business Development & Strategy acted as transaction advisor to Luxendo.

About EMBL
EMBL is Europe’s flagship laboratory for the life sciences. We are an intergovernmental organisation established in 1974 and are supported by over 20 member states.

EMBL performs fundamental research in molecular biology, studying the story of life. We offer services to the scientific community; train the next generation of scientists and strive to integrate the life sciences across Europe.

We are international, innovative and interdisciplinary. We are more than 1600 people, from over 80 countries, operating across six sites in Barcelona (Spain), Grenoble (France), Hamburg (Germany), Heidelberg (Germany), Hinxton (UK) and Monterotondo (Italy). Our scientists work in independent groups and conduct research and offer services in all areas of molecular biology.

Our research drives the development of new technology and methods in the life sciences. We work to transfer this knowledge for the benefit of society.
For more information, please visit EMBL's website.

About EMBLEM
EMBLEM, established in 1999, identifies, protects and commercialises the intellectual property developed in the EMBL world, from EMBL alumni and from non-EMBL third parties. EMBLEM currently manages a portfolio of more than 350 granted patents and patent applications, and has created 18 spin-out companies. EMBLEM facilitates and accelerates the transfer of innovative technology from basic research to industry by working closely with industrial partners spanning the biotech, IT and mechanical/electrical engineering markets and currently has more than 300 licencees of EMBL technologies. For more information, please visit EMBLEM's website.

About Bruker Corporation (NASDAQ: BRKR)

For more than 50 years, Bruker has enabled scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific research instruments and high-value analytical solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels.

In close cooperation with our customers, Bruker is enabling innovation, productivity and customer success in life science molecular research, in applied and pharma applications, in microscopy, nano-analysis and industrial applications, as well as in cell biology, preclinical imaging, clinical research, microbiology and molecular diagnostics. For more information, please visit Bruker's website.

Press contact

EMBL
Iris Kruijen, Press Officer
iris.kruijen@embl.de

EMBLEM
Dr. Jürgen Bauer, Deputy Managing Director
bauer@embl-em.de

Policy regarding use

Press and Picture Releases

EMBL press and picture releases including photographs, graphics, movies and videos are copyrighted by EMBL. They may be freely reprinted and distributed for non-commercial use via print, broadcast and electronic media, provided that proper attribution to authors, photographers and designers is made.